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Abstract 
Aim 
Boiogito (BOT) and bofutsushosan (BTS) are major traditional Kampo medicines 
that have been widely used for obesity in Japan. In this study, we employed a 
high-fat diet-induced obesity (DIO) mouse model to conduct a comparative study 
of BOT and BTS for their therapeutic efficacy in obesity. 
 
Methods 
C57BL/6J mice were fed a high-fat diet (HFD) for 10 weeks for developing the 
DIO mouse model and were treated with Kampo medicines for 12 weeks. Body 
weight and food intake were monitored weekly and blood and tissue samples 
were collected. 
 
Results 
While neither BOT nor BTS showed any significant impact on body composition 
in the DIO mice, the serum level of leptin was significantly decreased in both 
BOT- and BTS-treated DIO mice. Contrary to blood leptin level, BOT suppressed, 
whereas BTS rather increased, the blood insulin level in the DIO mice. In 
addition to these serum obesity markers, BOT showed reduction of liver 
triglyceride and total cholesterol contents along with less steatosis. Importantly, 
mRNA expression of molecules associated with lipid metabolism was reduced in 
the DIO mice treated with BOT, whereas BTS treatment showed instead reduced 
liver mRNA expression of TNF-!. Both BOT and BTS treatment inhibited 
adipocyte maturation, as seen in the enlarged size of adipocytes in the white 
adipose tissue of DIO mice.  
 
Conclusion  
We conclude that BOT and BTS have a differential therapeutic benefit in obesity 
through their modulating activity in lipid metabolism and/or anti-inflammatory 
effect.  
 
Introduction 
 
Traditional Japanese/Chinese (Kampo) medicines have been established 
through the accumulation of extensive knowledge and experience [1]. Kampo 
medicines have been used as formulations of several crude drugs, prepared by 
decoction, and mostly administered orally. Since 1976, the Ministry of Health, 
Labor and Welfare of Japan has approved 148 of Kampo medicines to be 
covered by the national health insurance system [2]. Boiogito (BOT) and 
bofutsushosan (BTS) are major formulations that have been widely used for 
obesity in Japan among approved Kampo medicines. While BOT is used for the 
treatment of hyperhidrosis, obesity, arthritis, edema, and a tendency toward 
being easily fatigued, BTS is used for the treatment of thick subcutaneous 
abdominal fat, constipation and obesity [3]. Although these two Kampo 
formulations are often used in the clinic to treat obesity, their mechanism of 
action and any distinction in their efficacy remain unsolved [1]. 
 In this study, we employed one of the major pre-clinical animal models 
for studying obesity, which is the high-fat diet-induced obesity model, to conduct 
a comparative study of BOT and BTS for their therapeutic efficacy in obesity. 
The high-fat diet-induced obesity model has been known to share many of the 
same phenotypes as in human disease, including visceral adiposity, insulin 
resistance, hyperinsulinemia, hyperleptinemia, and leptin resistance [4, 5]. 
Although neither BOT nor BTS showed any significant impact on body 
composition in the DIO mice, BOT and BTS treatment altered the serum level of 
leptin and insulin in the DIO mice. In addition, BOT treatment showed a 
reduction in liver lipid contents, mRNA expression of molecules associated with 
lipid metabolism, and less steatosis at pathology. Distinct from BOT, BTS 
treatment significantly reduced the liver mRNA expression of TNF-!, which is a 
typical inflammatory mediator and known to be an important risk factor in obesity 
[6]. Both BOT and BTS treatment inhibited adipocyte maturation, as seen in the 
enlarged size of the DIO mice. Collectively, BOT and BTS may have a 
differential therapeutic benefit in obesity through their modulating activity in lipid 
metabolism and anti-inflammatory effect, respectively.  
 
Materials and methods 
 
Preparation of boiogito (BOT) and bofutsushosan (BTS) 
The extracts of BOT (TJ-20) and BTS (TJ-62) were kindly provided by Tsumura 
& Co. (Tokyo, Japan). The 3D-HPLC charts of the BOT and BTS extracts 
provided from Tsumura & Co. are shown in Figure 1 for quality reference. 
 
Animal experiments 
C57BL/6J mice (5-week old, male) were purchased from Japan SLC Inc. 
(Hamamatsu, Japan). All experiments were approved by and performed 
according to the guidelines of the Care and Use of Laboratory Animals of the 
University of Toyama. For developing the diet-induced obesity (DIO) mouse 
model, a group of C57BL/6J mice were fed a high-fat diet (HFD, D12492, 
Research Diets Inc., NJ, USA) for 10 weeks. Another group of mice were fed a 
normal diet (ND, D12450B, Research Diets Inc.) as a control. After 10 weeks of 
high-fat diet feeding, the DIO mice were divided into three groups with similar 
average of body weight and treated with BOT, BTS (orally with gavage, daily at 
500mg/kg dose) or control water for 12 weeks. The dose for Kampo medicines 
was determined by following to previous studies [7]. Upon 8 weeks’ treatment 
with BOT, BTS or water, an interim retro-orbital blood sample collection was 
conducted and then all mice were given a normal chow (Labo MR Stock) for 
another 4 weeks. On termination of the experiment, blood and tissue samples 
were collected. Body weight and food intake were monitored weekly. 
 
Serum measurements 
Serum leptin or insulin levels were determined by using a specific enzyme-linked 
immunosorbent assay (ELISA) according to the manufacturer’s instructions. The 
ELISA kit for rat and mouse leptin (Lbis Leptin-Rat kit or Lbis Leptin-Mouse kit), 
and rat insulin kit (Lbis insulin-Rat kit) were purchased from Shibayagi Co. Ltd. 
(Shibukawa, Japan.) kit. The mouse insulin ELISA kit was purchased from 
Morinaga & Co. (Yokohama, Japan). 
 
Liver lipid content measurements 
The perfused liver tissues were weighed and homogenized in sodium chloride 
buffer and then the homogenates were extracted with 5 ml of chloroform and 
methanol (2:1, vol/vol) [8]. The chloroform layers were dried and then triglyceride 
(TG), total cholesterol (Cholesterol) or free fatty acids (FFA) were measured by 
using LabAssay Cholesterol kit, LabAssay triglyceride kit, LabAssay NEEA kit 
(Wako Chemical, Osaka, Japan). 
 
Histological analysis  
Liver and epididymal adipose tissues were collected upon termination of the 
experiment and immediately fixed with 4% PFA for 1-2 days. The fixed tissue 
samples were then sliced sequentially into sections 3-5 µm in thickness. 
Representative sections of the liver and fat tissues 2-3 µm thick were selected 
and embedded in paraffin for routine histo-pathological analysis with 
hematoxylin and eosin (H&E) staining. Adipocytes in white adipose tissue were 
counted with a microscope at x200 magnification. Three visual fields were 
chosen randomly and the average number of adipocytes in the three fields was 
taken for each group. Macrovesicular steatosis was graded on a scale 0 to 4 
based on the percentage of hepatocytes affected in each specimen. The score 
was 0 for none; 1 for up to 33%; 2 for 3366%; 3 for more than 66%; and 4 for 
more than 66%-100%. 
 
Real-time RT-PCR for quantitative assessment of mRNA expression 
Total&RNAs&were&prepared&using&the&RNeasy&Plus&Mini&kit&(QIAGEN,&Hilden,&
Germany).&The&expression&level&of&targeted&mRNAs&was&normalized&to&mGapdh&
mRNA&by&using One Step SYBR PrimeScript RT-PCR kit II (Takara, Kyoto, 
Japan). The primers used in this experiment are listed in Table 1. 
 
Statistics 
Statistical analysis was performed with JMP (SAS Institute Japan, Tokyo). Data 
were expressed as mean ± S.E.M. One-way ANOVA followed by Dunnett’s test 
was used to determine the statistical differences among groups.
Results 
 
Effect of BOT and BTS on body weight changes and tissue weight in DIO 
model  
In order to conduct a comparative study of the two major Kampo medicines, 
BOT and BTS, in a dietary obesity model, we employed a high-fat diet-induced 
obesity (DIO) mouse model in C57BL/6 mice. Mice were fed a high-fat diet (HFD) 
for 8 weeks before being subjected to BOT or BTS treatment. The HFD-treated 
mice significantly gained the body weight, compared with the ND group. Neither 
BOT nor BTS treatment affected on either body weight (Fig. 2A) in the chronic 
DIO mice (up to 8 weeks). We then further monitored the efficacy of BOT or BTS 
in combination with a diet modification by feeding mice a standard diet for a 
subsequent 4 weeks from the 8-week time point. Even in this situation, we did 
not observe any significant effect on body weight, epididymal fat (Fig. 2B), or 
liver weight (Fig. 2C) at the time of termination. Collectively, BOT and BTS did 
not show any dynamic efficacy on either body or tissue weight gain in the DIO 
model. 
 
Effect of BOT and BTS on the level of serum biomarkers and liver lipid 
contents in the DIO model  
We then investigated whether BOT or BTS treatment affects on the 
obesity-associated serum biomarkers. The DIO mice treated with both BOT and 
BTS showed significantly lower levels of serum leptin both in the chronic disease 
state (Fig. 3A left) and in combination with the diet modification (Fig. 3 A left). 
While BOT treatment showed lower serum insulin levels in the DIO mice 
compared to the untreated NFD group, BTS treatment rather enhanced serum 
insulin level in the chronic disease state (Fig. 3 A right). Neither BOT nor BTS 
treatment affected serum insulin levels in combination with the diet modification 
(Fig. 3B right). To further explore a therapeutic effect of BOT or BTS in the DIO 
model, we examined the effect of BOT or BTS on the expression of liver lipids in 
the DIO mice. While BTS treatment did not show any significant effect on the 
liver lipid contents, the liver TG level and the total cholesterol, but not the free 
fatty acid (FFN), were significantly lower in BOT-treated DIO mice than in the 
HFD mice (Fig. 4). 
 
Effect of BOT and BTS on lipid metabolisms in the DIO model 
Along with the reduction in liver lipid contents in BOT-treated DIO mice (Fig. 4), 
we observed less fat deposition in the liver of DIO mice treated with BOT, but not 
BTS, as seen in the lower steatosis score (Fig. 5A and B). Furthermore, the size 
of adipocytes in white adipose tissue, which was enlarged in the DIO mice, was 
relatively smaller with BOT treatment or BTS treatment (Fig. 5A), as seen in the 
increased number of adipocytes on histological examination (Fig. 5C). We then 
examined the effect of BOT or BTS on the liver mRNA expression of molecules 
associated with obesity to understand the potential molecular mechanism for in 
vivo efficacy of BOT or BTS by using quantitative real-time polymerase chain 
reaction (PCR). Among many molecules associated with obesity, we found that 
the wide spectrum of mRNA expression that associated with lipid metabolism, 
Lipe, Lpl, PPAR!, Cpt1! and SREBP1, were significantly decreased by BOT 
treatment in DIO mice. Distinct from BOT treatment, BTS significantly reduced 
the expression of TNF-! mRNA, but did not affect the expression of mRNA 
associated with lipid metabolism.  
Discussion 
 
Boiogito (BOT) and Bofutsushosan (BTS) are major herbal medicines that have 
been widely used for obesity in Japan [3, 9, 10]. Although there are several 
reports studying the effect of these herbal medicines, it is not yet clear whether 
there is any difference between BOT and BTS in their efficacy in obesity. In this 
study, we employed one of the major pre-clinical animal models for studying 
obesity, which is the high-fat diet-induced obesity model, to conduct a 
comparative study of BOT and BTS for their therapeutic efficacy in obesity.  
 While neither BOT nor BTS showed any significant impact on the body 
composition of DIO mice, the serum level of leptin significantly decreased in 
BOT- and BTS-treated DIO mice (Fig. 3A). This effect of BOT and BTS in 
reducing blood leptin level was more significant in combination with food 
restriction (Fig. 3B). As leptin has been widely known as a potent lipid-lowering 
adipokine and is considered an important factor for preventing cellular 
lipotoxicity and insulin resistance [11, 12], the modulating effect of BOT or BTS 
on the systemic leptin level may be partially involved in their mechanism of 
action in vivo. Contrary to the similar effect on blood leptin level, BOT 
suppressed whereas BTS rather increased the blood insulin level in the DIO 
mice. These results imply a distinct effect of BOT and BTS on insulin resistance 
in the chronic obesity condition.  
 In addition to the serum obesity markers, BOT showed a reduction in 
liver TG and total the cholesterol contents (Fig. 4), along with the lower steatosis 
score (Fig 5A and B). Importantly, we observed the reduction of liver mRNA 
expression of molecules associated with lipid metabolism (Lipe, Lpl, PPAR!, 
Cpt1! and SREBP1) [13-15] in DIO mice treated with BOT (Fig. 6). BTS 
treatment did not show a significant effect on liver lipid metabolism in contrast to 
BOT treatment. Instead, there was a significant reduction in the liver mRNA 
expression of TNF-!, which is a typical inflammatory mediator and known to be 
an important risk factor in obesity. Recent studies have indicated that TNF-! 
plays an important role in mediating the insulin resistance of obesity through its 
over-expression in fat tissue [16, 17]. Considering both BOT and BTS treatment 
inhibited adipocyte maturation, as seen in their enlarged size in DIO mice, BOT 
and BTS may have a differential therapeutic benefit in obesity and such 
anti-obesity effect may be through their modulating activity in lipid metabolism 
and anti-inflammatory effect, respectively. Considering not only the body weight 
loss rather the improvement of obesity-related pathogenic status can be critical 
for treating obesity, we believe our presented results clearly indicate both BOT 
and BTS have anti-obesity effect without affecting the body composition of HFD 
mice. Nevertheless, considering that neither BOT nor BTS treatment was solely 
effective in DIO mice maintained on an HFD feeding condition (data not shown), 
we propose that the two major Kampo medicines, BOT and BTS, are better 
utilized for their optimal anti-obesity effect in the presence of diet therapy. 
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Figure legends 
 
Figure 1. Analysis by three-dimensional HPLC of major chemical 
compounds included in Kampo extracts.  
The 3D-HPLC chart of major chemical compounds included in (A) boiogito (BOT) 
and (B) bofutsushosan (BTS) is shown. 
 
Figure 2. Effect of BOT or BTS on body and tissue weight in obesity 
models.  
C57BL/6 mice were pre-fed a normal diet (ND) or high-fat diet (HFD) for 10 
weeks, and then administered control water or Kampo extracts (500 mg/kg, p.o., 
daily) for 12 weeks under the same feeding conditions. After 8 weeks of control 
or Kampo extract treatment, mice fed with HFD were changed to ND until 
termination of the experiment while maintaining the Kampo extract treatment for 
another 4 weeks. Body weight changes (A) and tissue weight (B: fat and C: liver) 
of DIO mouse are shown. Data are mean ± SEM (n=7-15). 
 
Figure 3. Effect of BOT or BTS on serum levels of leptin and insulin in 
obesity models.  
C57BL/6 mice were pre-fed a normal diet (ND) or high-fat diet (HFD) for 10 
weeks, and then administered control water or Kampo extracts (500 mg/kg, p.o., 
daily) for 12 weeks under the same feeding conditions. After 8 weeks of control 
or Kampo extract treatment, mice fed with HFD were changed to ND until 
termination of the experiment while maintaining the Kampo extract treatment for 
another 4 weeks. Serum samples were collected before the change in food (A) 
or upon termination (B), and levels of leptin (left) or insulin (right) were measured 
by using specific ELISA assay. Data are mean ± SEM (n=7-15). * p<0.005, ** 
p<0.001 as compared with the HFD group. 
 
Figure 4. Effect of BOT or BTS on liver lipid levels in DIO mice.  
C57BL/6 mice were pre-fed with a normal diet (ND) or high-fat diet (HFD) for 10 
weeks, and then administered control water or Kampo extracts (500 mg/kg, p.o., 
daily) for 12 weeks under the same feeding conditions. After 8 weeks of control 
or Kampo extract treatment, mice fed with HFD were changed to ND until 
termination of the experiment while maintaining the Kampo extract treatment for 
another 4 weeks. Liver tissue samples were collected upon termination and 
levels of triglyceride (TG, left), total cholesterol (Cholesterol, middle) or free fatty 
acid (FAA, right) were measured. Data are mean ± SEM (n=7-15). * p<0.005 as 
compared with the HFD group. 
 
Figure 5. Histopathological evaluation of fat and liver tissue in DIO mice.  
C57BL/6 mice were pre-fed with a normal diet (ND) or high-fat diet (HFD) for 10 
weeks, and then administered control water or Kampo extracts (500 mg/kg, p.o., 
daily) for 12 weeks under the same feeding conditions. After 8 weeks of control 
or Kampo extract treatment, mice fed with HFD were changed to ND until 
termination of the experiment while maintaining the Kampo extract treatment for 
another 4 weeks. (A) Representative images (x 200) of H&E staining of liver (left 
panels) and white adipose tissue (right panels) of DIO mice are shown. (B) 
Steatosis scores of DIO mice. (C) Observed number of adipocyte counts of WAT 
in DIO mice. Data are mean ± SEM (n=7-15). ** p<0.001 as compared with the 
HFD group. 
 
Figure 6. Effect of KBG on obesity-associated gene expression in liver 
tissue of DIO mice. 
C57BL/6 mice were pre-fed with a normal diet (ND) or high-fat diet (HFD) for 10 
weeks, and then administered control water or Kampo extracts (500 mg/kg, p.o., 
daily) for 12 weeks under the same feeding conditions. After 8 weeks of control 
or Kampo extract treatment, mice fed with HFD were changed to ND until 
termination of the experiment while maintaining the Kampo extract treatment for 
another 4 weeks. Liver tissue samples were collected upon termination and the 
relative expression of indicated obesity-associated genes was determined by 
RT-PCR and shown as relative expression to HFD group (HFD = 1). Data are 
mean ± SEM (n=7-15). * p<0.005, ** p<0.001 as compared with the HFD group. 
Table 1. Sequences of the primers used in real-time PCR of the mouse 
tissue. 
 
Gene Forward primer Reverse primer 
Lipase (Lipe) CAGGCTCACAGTTACCATCTC TGTCCTTCCCGTAGGTCATA 
LPL GCCCGAGGTTTCCACAAATA GCTGAAGTAGGAGTCGCTTATC 
PPAR" GAACCTGCATCTCCACCTTATT TGGAAGCCTGATGCTTTATCC 
PPAR! CGGTGTGTATGAAGCCATCT TAAGGAACTCGCGTGTGATAAA 
Cpt1! CTCTGCTGCATGGTAGATGTT GCTCTGCGTTTATGCCTATCT 
SREBP1 CATCGACTACATCCGCTTCTT CACCAGGTCCTTCAGTGATTT 
TNF-! AAGCCTGTAGCCCACGTCGTA GGCACCACTAGTTGGTTGTCTTTG 
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